Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559895 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
A Phase 3 study of Migraine Disorders, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 898
- Enrollment target
- 20
- Study locations
NCT02559895 is a Phase 3 study of Migraine Disorders that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 898 participants, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (230% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT02559895, a Phase 3 study of Migraine Disorders, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 898 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALD403
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Fresno
- Research Site - Fullerton
- Research Site - Long Beach
- Research Site - Montclair
- Research Site - Oceanside
- Research Site - Redlands
- Research Site - San Diego
- Research Site - San Diego
- Research Site - Santa Monica
- Research Site - Sherman Oaks
Arizona
- Research Site - Phoenix
- Research Site - Tucson
Colorado
- Research Site - Colorado Springs
- Research Site - Fort Collins
Connecticut
- Research Site - Stamford
- Research Site - Waterbury
Alabama
- Research Site - Birmingham
Arkansas
- Research Site - Little Rock
Florida
- Research Site - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 898 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02559895
The ClinicalTrials.gov registry entry for NCT02559895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 898 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (230% higher). The listed sponsor is Alder Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02559895 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT02559895 about?
NCT02559895 is a clinical study titled "A Multicenter Assessment of ALD403 in Frequent Episodic Migraine". The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
What is the current status of trial NCT02559895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 898 participants. The study started on 2015-09. Estimated completion is 2017-12.
What conditions does trial NCT02559895 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT02559895?
The interventions under investigation include: Placebo (DRUG), ALD403 (DRUG).
Who is sponsoring clinical trial NCT02559895?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02559895 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of MAP0004 in Adult Migraineurs
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.